Referencia número: HY-107370

Atomoxetine

(Synonyms: Tomoxetine; (R)-Tomoxetine)

4 Cited Publications

Revisión del cliente

Based on 4 publication(s) in Google Scholar

Atomoxetine (Tomoxetine) is a selective noradrenaline reuptake inhibitor with K_i values of 5, 77 and 1451 nM for norepinephrine (NE), serotonin (5-HT) and dopamine (DA) transporters, respectively. Atomoxetine (Tomoxetine) increases of DA_EX and NE_EX in the PFC and enhances catecholaminergic neurotransmission. Atomoxetine (Tomoxetine) is a potent Na⁺ channels (VGSCs) blocker. Atomoxetine (Tomoxetine) can be used for attention-deficit hyperactivity disorder (ADHD) research.

Para uso exclusivo en investigación. No vendemos a pacientes.

Pureza: 98.50%
No. CAS: 83015-26-3
Fòrmula: C₁₇H₂₁NO
Peso molecular:255.35

Almacenamiento:

Pure form -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Atomoxetine Chemical Structure

No. CAS: 83015-26-3

Tamaño

Precio

Stock

Cantidad

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Obtener un presupuesto Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Obtener un presupuesto Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Consulta para venta a granel

Amount: USD 0.00

* Seleccione Cantidad antes de agregar artículos.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Actividad biológica
- Descripciòn
- Cellular Effect
- In Vitro
- In Vivo
- Ensayo clínico
Chemical Information
Publications (4)
Solvente y solubilidad
- In Vitro
- In Vivo
Pureza y Documentación
Referencias
Help & FAQs
Bioz

Actividad biológica

Descripciòn

Ver todos los productos específicos de isoformas Sodium Channel :

Cellular Effect

Cell Line	Type	Value	Description	References
HEK293	IC₅₀	>5000 nM Compound: 6 (Atomoxetine)	Inhibitory activity against Opioid receptor like 1 expressed in HEK293 cells Inhibitory activity against Opioid receptor like 1 expressed in HEK293 cells	[PMID: 15225731]
HEK293	IC₅₀	4186 nM Compound: 6 (Atomoxetine)	Inhibitory activity against Opioid receptor mu 1 expressed in HEK293 cells Inhibitory activity against Opioid receptor mu 1 expressed in HEK293 cells	[PMID: 15225731]
HEK293	IC₅₀	4383 nM Compound: 6 (Atomoxetine)	Inhibitory activity against Opioid receptor kappa 1 expressed in HEK293 cells Inhibitory activity against Opioid receptor kappa 1 expressed in HEK293 cells	[PMID: 15225731]
HEK293	IC₅₀	>5000 nM Compound: 6 (Atomoxetine)	Inhibitory activity against Opioid receptor delta 1 expressed in HEK293 cells Inhibitory activity against Opioid receptor delta 1 expressed in HEK293 cells	[PMID: 15225731]
HEK293	IC₅₀	180 nM Compound: 1	Inhibition of serotonin uptake at human SERT in human HEK293 cells Inhibition of serotonin uptake at human SERT in human HEK293 cells	[PMID: 18550369]
HEK293	IC₅₀	5 nM Compound: 1	Inhibition of norepinephrine uptake at human NET in human HEK293 cells Inhibition of norepinephrine uptake at human NET in human HEK293 cells	[PMID: 18550369]
HEK293	IC₅₀	3 μM Compound: 1	Inhibition of dopamine uptake at human DAT in human HEK293 cells Inhibition of dopamine uptake at human DAT in human HEK293 cells	[PMID: 18550369]
HEK293	IC₅₀	180 nM Compound: 1	Inhibition of serotonin uptake at human SERT expressed in HEK cells Inhibition of serotonin uptake at human SERT expressed in HEK cells	[PMID: 18667309]
HEK293	IC₅₀	5 nM Compound: 1	Inhibition of norepinephrine uptake at human NET expressed in HEK cells Inhibition of norepinephrine uptake at human NET expressed in HEK cells	[PMID: 18667309]
HEK293	IC₅₀	3 μM Compound: 1	Inhibition of dopamine uptake at human DAT expressed in HEK cells Inhibition of dopamine uptake at human DAT expressed in HEK cells	[PMID: 18667309]
HEK293	IC₅₀	180 nM Compound: atomoxetine	Inhibition of serotonin uptake at human SERT expressed in HEK293 cells Inhibition of serotonin uptake at human SERT expressed in HEK293 cells	[PMID: 18672364]
HEK293	IC₅₀	5 nM Compound: atomoxetine	Inhibition of norepinephrine uptake at human NET expressed in HEK293 cells Inhibition of norepinephrine uptake at human NET expressed in HEK293 cells	[PMID: 18672364]
HEK293	IC₅₀	3 μM Compound: atomoxetine	Inhibition of dopamine uptake at human DAT expressed in HEK293 cells Inhibition of dopamine uptake at human DAT expressed in HEK293 cells	[PMID: 18672364]
HEK293	IC₅₀	190 nM Compound: 6	Displacement of [alpha,beta-3H(N)]-5-hydroxytryptamine from human cloned SERT expressed in HEK293 cells by microplate scintillation counter Displacement of [alpha,beta-3H(N)]-5-hydroxytryptamine from human cloned SERT expressed in HEK293 cells by microplate scintillation counter	[PMID: 18954038]
HEK293	IC₅₀	2.1 μM Compound: 6	Inhibition of human ERG expressed in HEK293 cells by patch-clamp method Inhibition of human ERG expressed in HEK293 cells by patch-clamp method	[PMID: 18954038]
HEK293	IC₅₀	3100 nM Compound: 6	Displacement of 3,4-[ring-2,5,6-3H]dihydroxyphenylethylamine from human cloned DAT expressed in HEK293 cells by microplate scintillation counter Displacement of 3,4-[ring-2,5,6-3H]dihydroxyphenylethylamine from human cloned DAT expressed in HEK293 cells by microplate scintillation counter	[PMID: 18954038]
HEK293	IC₅₀	5.1 nM Compound: 6	Displacement of Levo[ring-2,5,6-3H]norepinephrine from human cloned NET expressed in HEK293 cells by microplate scintillation counter Displacement of Levo[ring-2,5,6-3H]norepinephrine from human cloned NET expressed in HEK293 cells by microplate scintillation counter	[PMID: 18954038]
HEK293	IC₅₀	180 nM Compound: atomoxetine	Inhibition of serotonin uptake at human SERT transfected in HEK cells Inhibition of serotonin uptake at human SERT transfected in HEK cells	[PMID: 18954981]
HEK293	IC₅₀	5 nM Compound: atomoxetine	Inhibition of norepinephrine uptake at human NET transfected in HEK cells Inhibition of norepinephrine uptake at human NET transfected in HEK cells	[PMID: 18954981]
HEK293	IC₅₀	3 μM Compound: atomoxetine	Inhibition of dopamine uptake at human DAT transfected in HEK cells Inhibition of dopamine uptake at human DAT transfected in HEK cells	[PMID: 18954981]
HeLa	IC₅₀	100 μM Compound: Atomoxetine	Inhibition of human KLF10 expressed in human HeLa cells assessed as reduction in transcriptional activity after 24 hrs by CACCC-responsive promoter driven TK-luciferase reporter gene assay Inhibition of human KLF10 expressed in human HeLa cells assessed as reduction in transcriptional activity after 24 hrs by CACCC-responsive promoter driven TK-luciferase reporter gene assay	[PMID: 25581017]
JAR	IC₅₀	48 nM Compound: 4	Inhibition of serotonin uptake at human SERT expressed in JAR cells Inhibition of serotonin uptake at human SERT expressed in JAR cells	[PMID: 18771916]
JAR	IC₅₀	48 nM Compound: 5	Inhibition of serotonin uptake at human SERT expressed in JAR cells Inhibition of serotonin uptake at human SERT expressed in JAR cells	[PMID: 18951020]
JAR	IC₅₀	48 nM Compound: 2	Inhibition of serotonin uptake at human SERT expressed in human JAR cells Inhibition of serotonin uptake at human SERT expressed in human JAR cells	[PMID: 19329313]
MDCK	IC₅₀	3 nM Compound: 4	Inhibition of norepinephrine uptake at human NET expressed in MDCK cells Inhibition of norepinephrine uptake at human NET expressed in MDCK cells	[PMID: 18771916]

In Vitro

Atomoxetine (Tomoxetine) (1-100 μM; 0.5-20 seconds; tsA201 cells) interacts with the human heart muscle sodium channel (hNa_v1.5) in a state and dose-dependent manner^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Atomoxetine (Tomoxetine) (0.3-3 mg/kg; i.p.; 0-4 hours; male Sprague-Dawley rats) increases extracellular norepinephrine and dopamine by 3-fold and increases Fos expression in the rat prefrontal cortex^[1].
Atomoxetine (Tomoxetine) (0.1-5 mg/kg; i.p. and p.o; for 14 days; spontaneously hypertensive rat) can improve behaviors associated with ADHD in rats^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Male Sprague-Dawley rats^[1]
Dosage:

0.3, 1 and 3 mg/kg
Administration:

Intraperitoneal injection; for 4 hours
Result:

Increased the number of cells expressing Fos-like immunoreactivity in PFC 3.7-fold and increased extracellular norepinephrine and dopamine by 3-fold.

Animal Model:

Spontaneously hypertensive rat (SHR)^[3]
Dosage:

0.1, 0.3, 1.25 and 5.0 mg/kg
Administration:

Intraperitoneal injection and oral administration; for 14 days
Result:

Had non-impact on the measurement of motor activity.

Ensayo clínico

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

No. CAS 83015-26-3
Appearance Oil
Peso molecular 255.35
Fòrmula C₁₇H₂₁NO
Color Colorless to light yellow
SMILES

CC(C=CC=C1)=C1O[C@@H](C2=CC=CC=C2)CCNC
Synonyms

Tomoxetine; (R)-Tomoxetine
Envío

Room temperature in continental US; may vary elsewhere.

Almacenamiento

Pure form	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (4)

All

Sort by:

Journal Impact Factor

Brain Behav Immun

Ghrelin modulates dopaminergic neuron formation and attention deficit hyperactivity disorder-like behaviors: From animals to human models. [Abstract]

2021 May:94:327-337. PMID: 33412253
Ecotoxicol Environ Saf

Long-life triclosan exposure induces ADHD-like behavior in rats via prefrontal cortex dopaminergic deficiency. [Abstract]

2024 Jul 23:282:116766. PMID: 39047361
Behav Brain Res

Manipulation of vocal communication and anxiety through pharmacologic modulation of norepinephrine in the Pink1-/- rat model of Parkinson disease. [Abstract]

2022 Feb 10:418:113642. PMID: 34755639
University of Dublin

2019 Mar.

Solvente y solubilidad

In Vitro:

DMSO : 100 mg/mL (391.62 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.9162 mL

19.5810 mL

39.1619 mL

5 mM

0.7832 mL

3.9162 mL

7.8324 mL

10 mM

0.3916 mL

1.9581 mL

3.9162 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculadora de molaridad

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculadora de dilución

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (9.79 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (9.79 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (9.79 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Pureza y Documentación

Select Batch:

Pureza: 99.98%

Assay: 99.98%

ee.: 99.98%

Ficha de datos (297 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instrucciones de manejo (2659 KB)

Referencias

[1]. Turner M, et, al. Effects of atomoxetine on locomotor activity and impulsivity in the spontaneously hypertensive rat. Behav Brain Res. 2013 Apr 15;243:28-37. [Content Brief]

[2]. Föhr KJ, et, al. Block of Voltage-Gated Sodium Channels by Atomoxetine in a State- and Use-dependent Manner. Front Pharmacol. 2021 Feb 25;12:622489. [Content Brief]

[3]. Bymaster FP, et, al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology. 2002 Nov;27(5):699-711. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.9162 mL	19.5810 mL	39.1619 mL	97.9048 mL
	5 mM	0.7832 mL	3.9162 mL	7.8324 mL	19.5810 mL
	10 mM	0.3916 mL	1.9581 mL	3.9162 mL	9.7905 mL
	15 mM	0.2611 mL	1.3054 mL	2.6108 mL	6.5270 mL
	20 mM	0.1958 mL	0.9790 mL	1.9581 mL	4.8952 mL
	25 mM	0.1566 mL	0.7832 mL	1.5665 mL	3.9162 mL
	30 mM	0.1305 mL	0.6527 mL	1.3054 mL	3.2635 mL
	40 mM	0.0979 mL	0.4895 mL	0.9790 mL	2.4476 mL
	50 mM	0.0783 mL	0.3916 mL	0.7832 mL	1.9581 mL
	60 mM	0.0653 mL	0.3263 mL	0.6527 mL	1.6317 mL
	80 mM	0.0490 mL	0.2448 mL	0.4895 mL	1.2238 mL
	100 mM	0.0392 mL	0.1958 mL	0.3916 mL	0.9790 mL

Keywords

Atomoxetine

4 Cited Publications

100 mg Obtener un presupuesto

Subscribe to the

MedChemExpress

Newsletter

Nombre del producto:
Referencia número:
Cantidad:
MCE Japan Authorized Agent:

Nombre del producto:
No. CAS:
Species:
Pureza:
Cantidad:

Atomoxetine

Membrane Transporter/Ion Channel Compound Library

Neuronal Signaling Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Drug Repurposing Compound Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Neuroprotective Compound Library

Rare Diseases Drug Library

Pediatric Drug Library

Antidepressant Compound Library

Sodium Channel Blocker Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Coagulation and Anti-coagulation Compound Library

Off-patent Drug Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Highly Selective Inhibitors Library

Ion Channel Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Publications Citing Use of MedChemExpress (MCE) Atomoxetine

Ver todos los productos específicos de isoformas Sodium Channel

Actividad biológica

Chemical Information

Publications (4)

Solvente y solubilidad

Pureza y Documentación

Referencias

Help & FAQs

Complete Stock Solution Preparation Table

Atomoxetine

Membrane Transporter/Ion Channel Compound Library

Neuronal Signaling Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Drug Repurposing Compound Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Neuroprotective Compound Library

Rare Diseases Drug Library

Pediatric Drug Library

Antidepressant Compound Library

Sodium Channel Blocker Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Coagulation and Anti-coagulation Compound Library

Off-patent Drug Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Highly Selective Inhibitors Library

Ion Channel Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Publications Citing Use of MedChemExpress (MCE) Atomoxetine

Ver todos los productos específicos de isoformas Sodium Channel

Actividad biológica

Chemical Information

Publications (4)

Solvente y solubilidad

Pureza y Documentación

Referencias

Help & FAQs

Complete Stock Solution Preparation Table

Atomoxetine Related Classifications

Referencia número: HY-107370